Statistics from Altmetric.com
We read with great interest the article by Villumsen et al 1 about the association between inflammatory bowel disease (IBD) and Parkinson’s disease (PD). Villumsen et al estimated the risk of developing PD to be 22% higher in a Danish IBD population than in a non-IBD population.
During the last decade, evidence has accumulated that shared biological mechanisms are involved in the development of IBD and PD.2 However, the clinical co-occurrence of IBD and PD has only been investigated to a limited extent and with inconsistent results.3–5 Thus, concerns have been raised about how best to interpret this possible association.
In a recently published article by our group, we too demonstrated a positive association between PD and IBD.6 We observed that Swedish patients with IBD were at 30% higher risk of subsequently developing PD than were non-IBD individuals. Furthermore, that patients with IBD had higher …
Contributors All authors made substantial contributions to the conception or design of the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Competing interests PW has received grants from Ferring lægemidler and Tillotts Pharma as well as non-financial support from Janssen-Cilag A/S, Calpro AS, Pharmacosmos A/S and Vifor Pharma Nordiska AB. JH has received consulting or lecture fees from Abbvie, Celgene, Ferring, Hospira, Janssen, Medivir, MSD, Pfizer, RenapharmaVifor, Sandoz, Shire Takeda and Tillotts Pharma Research grants from Janssen, MSD and Takeda. Karolinska Institutet has received fees for lectures held by OO on occasions organised by Takeda and Ferring. Karolinska Institutet has received fees when OO participated as an expert in a panel discussing possibilities with register-based research. Karolinska Institutet (OO PI) performed an observational study, in part financed by an unrestricted grant from Janssen pharmaceuticals and one observational report financed by Pfizer. JB has received consulting fees from Celgene, Janssen-Cilag, Abbvie and Ferring, lecture fees from Abbvie, Pfizer, MSD and Takeda and has received an unrestricted grant from Takeda.
Patient consent Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.